SCHEMBL7932770

SCHEMBL7932770

Cc1ccc(C(=O)Nc2ccnc(CNc3cccnc3N)c2)s1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 5/20 0.45
PRKCI P41743 2/20 0.45
SMN1; SMN2 Q16637 3/20 0.42
NPC1 O15118 4/20 0.42
RAB9A P51151 3/20 0.42
IKBKE Q14164 1/20 0.41
TBK1 Q9UHD2 1/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
HDAC3 O15379 2/20 0.40
ABL1 P00519 2/20 0.40
PDGFRB P09619 2/20 0.40
KDR P35968 2/20 0.40
HDAC4 P56524 2/20 0.40
HDAC1 Q13547 2/20 0.40
HDAC7 Q8WUI4 2/20 0.40
HDAC2 Q92769 2/20 0.40
HDAC10 Q969S8 2/20 0.40
HDAC11 Q96DB2 2/20 0.40
HDAC8 Q9BY41 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7941414 0.89 HPGD (0.50) BACE1PRKCISMN1; SMN2NPC1RAB9A
SCHEMBL12303677 0.87 BACE1 (0.49) BACE1PRKCISMN1; SMN2HDAC3ABL1
SCHEMBL7935774 0.87 BACE1 (0.43) BACE1PRKCIKMT2AHDAC3ABL1
SCHEMBL7942148 0.86 BACE1 (0.61) BACE1SMN1; SMN2NPC1RAB9AMEN1
SCHEMBL7944983 0.86 BACE1 (0.45) BACE1PRKCIIKBKETBK1VCP
SCHEMBL7940384 0.85 BACE1 (0.44) BACE1PRKCINPC1RAB9AHDAC1
SCHEMBL7944905 0.83 BACE1 (0.43) BACE1SMN1; SMN2NPC1RAB9AMEN1
SCHEMBL7945397 0.83 BACE1 (0.49) BACE1PRKCIHDAC3HDAC4HDAC1
SCHEMBL7935757 0.82 RAB9A (0.50) BACE1PRKCISMN1; SMN2NPC1RAB9A
SCHEMBL7934108 0.82 HDAC2 (0.46) BACE1PRKCITBK1HDAC3PDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY SHIONOGI & CO., LTD. (JP) 2011-09-29 US disclosed
EP-2360155-A1 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY Shionogi & Co., Ltd. (JP) 2011-08-24 EP disclosed
WO-2010047372-A1 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY 塩野義製薬株式会社 (JP) 2010-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY BACE1, APP, BACE2 BACE1 1/4885PRKCI 2747/4885SMN1; SMN2 576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.